Tema Heart & Health ETF (NASDAQ:HRTS) Sees Significant Decrease in Short Interest

Tema Heart & Health ETF (NASDAQ:HRTS) saw a large decline in short interest during the month of September. As of September 15th, there was short interest totaling 917 shares, a decline of 82.2% from the August 31st total of 5,158 shares. Based on an average trading volume of 2,266 shares, the short-interest ratio is presently 0.4 days. Approximately 0.1% of the shares of the stock are short sold.

Hedge Funds Weigh In On Tema Heart & Health ETF

Several institutional investors have recently modified their holdings of HRTS. Members Advisory Group LLC purchased a new position in shares of Tema Heart & Health ETF during the 2nd quarter valued at about $398,000. Rothschild Capital Partners LLC purchased a new stake in Tema Heart & Health ETF in the second quarter worth approximately $651,000. Anson Capital Inc. bought a new position in Tema Heart & Health ETF during the second quarter valued at approximately $297,000. Royal Bank of Canada raised its stake in shares of Tema Heart & Health ETF by 8.8% during the first quarter. Royal Bank of Canada now owns 21,083 shares of the company’s stock worth $710,000 after acquiring an additional 1,703 shares in the last quarter. Finally, XML Financial LLC purchased a new position in shares of Tema Heart & Health ETF during the second quarter worth approximately $223,000.

Tema Heart & Health ETF Stock Performance

HRTS traded up $0.06 during trading on Friday, reaching $36.30. The stock had a trading volume of 505 shares, compared to its average volume of 5,581. The business has a 50-day moving average of $37.07 and a 200-day moving average of $35.30. Tema Heart & Health ETF has a one year low of $29.54 and a one year high of $38.87. The stock has a market cap of $53.72 million, a PE ratio of 22.06 and a beta of 0.63.

Tema Heart & Health ETF Company Profile

The Tema Obesity & Cardiometabolic ETF (HRTS) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that concentrates on companies focused on the treatment of cardiovascular diseases and/or metabolic diseases from companies all around the world. Using both top-down and bottom-up stock selection, the fund identifies innovative companies deemed attractive. HRTS was launched on Nov 20, 2023 and is issued by Tema.